1.090USD-3.11%Mkt Cap: 13.49M USDP/E: —Last update: 2026-05-26
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap13.49M USD
Enterprise Value-24.98M USD
Revenue (TTM)9.35M USD
Gross Profit-50.47M USD
Net Income (TTM)-43.50M USD
Revenue/Share0.7470 USD
Last Price1.090 USD
Fiscal Year EndDec 2024
MR QuarterMar 2025
Employees82
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.21
PEG—
EV/EBITDA0.34
EV/Revenue-2.67
P/S1.54
P/B0.43
EPS (TTM)-4.83
EPS (Forward)-5.43
52W Range
0.811033% of range1.650
52W High1.650 USD
52W Low0.8110 USD
Profitability
Gross Margin0.00%
Oper. Margin-885.28%
EBITDA Margin0.00%
Profit Margin-98.99%
ROE-84.94%
ROA-52.70%
Growth
Revenue Growth-94.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-76.98M USD
CapEx (TTM)194.00K USD
FCF Margin-350.89%
FCF Yield-243.22%
Net Debt-39.68M USD
Net Debt/EBITDA0.55
Balance Sheet
Debt/Equity0.02
Current Ratio3.61
Quick Ratio2.92
Book Value/Sh2.714 USD
Cash/Share3.178 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJul 10, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.9.98M
Float12.34M
Insiders0.13%
Institutions3.16%
Short Interest
Short Ratio0.6d
Short % Float0.45%
Short % Out.0.29%
Shares Short35.80K
Short (prev mo.)130.56K
Technical
SMA 501.132 (-3.7%)
SMA 2000.9752 (+11.8%)
Beta0.83
S&P 52W Chg28.31%
Avg Vol (30d)10.15K
Avg Vol (10d)6.03K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—